Platelet Membrane Glycoprotein IIB Peptide (296-306) Mechani

Platelet Membrane Glycoprotein IIB Peptide (296-306): Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: a8301 inhibitor]
Platelet Membrane Glycoprotein IIB Peptide (296-306) is a synthetic peptide fragment corresponding to amino acids 296-306 of the human platelet membrane glycoprotein IIb (GPIIb), a critical component of the GPIIb/IIIa integrin complex. This integrin, also known as αIIbβ3, is a major receptor on the surface of platelets and plays a pivotal role in platelet aggregation and thrombus formation (Shattil et al., 1998, Blood). The GPIIb/IIIa complex mediates the binding of fibrinogen and other adhesive proteins, facilitating platelet-platelet interactions essential for hemostasis. The 296-306 peptide sequence is located within a functional domain implicated in ligand binding and conformational regulation of the integrin (Hynes, 2002, Cell). [Related: staurosporin]
The Platelet Membrane Glycoprotein IIB Peptide (296-306) has been developed as a research tool to study the molecular mechanisms of platelet aggregation, integrin-ligand interactions, and to serve as a potential template for the design of antithrombotic agents. By mimicking a critical region of the GPIIb protein, this peptide can competitively inhibit or modulate the binding of natural ligands, providing a valuable approach for dissecting the functional domains of the integrin and for screening novel therapeutic compounds. [Related: ferrostatin-1 mechanism of action]
Clinical Value and Applications
The clinical significance of targeting the GPIIb/IIIa integrin stems from its central role in thrombus formation, which underlies many cardiovascular diseases, including myocardial infarction, stroke, and deep vein thrombosis (Coller, 1990, Blood). Pharmacological inhibition of GPIIb/IIIa has been a cornerstone in the management of acute coronary syndromes and percutaneous coronary interventions. However, current GPIIb/IIIa antagonists, such as abciximab, eptifibatide, and tirofiban, are associated with bleeding risks and other adverse effects (Topol et al., 1999, NEJM).
The Platelet Membrane Glycoprotein IIB Peptide (296-306) offers a unique research platform for: 1. Elucidating the structural basis of ligand recognition and integrin activation. 2. Screening and characterizing novel antiplatelet agents with improved safety profiles. 3. Investigating the molecular pathology of inherited platelet disorders, such as Glanzmann thrombasthenia, which involve mutations in the GPIIb/IIIa complex (Nurden & Caen, 1974, Nature). 4. Developing peptide-based therapeutics or diagnostic probes for thrombotic diseases.
Key Challenges and Pain Points Addressed
Despite the efficacy of current GPIIb/IIIa inhibitors, several challenges persist in clinical and research settings: - **Bleeding Complications**: Non-specific inhibition of platelet aggregation increases the risk of major bleeding events (Kereiakes et al., 2000, Circulation). - **Drug Resistance and Variability**: Genetic polymorphisms and acquired resistance can limit the effectiveness of existing therapies (Michelson, 1996, Circulation). - **Limited Mechanistic Understanding**: The conformational dynamics and ligand specificity of GPIIb/IIIa remain incompletely understood, hindering the rational design of safer inhibitors (Springer, 1997, Cell). - **Need for Selective Modulators**: There is a demand for agents that selectively modulate integrin function without completely abolishing platelet activity, to minimize adverse effects.
The Platelet Membrane Glycoprotein IIB Peptide (296-306) addresses these pain points by providing a precise molecular tool for dissecting integrin-ligand interactions, enabling high-resolution studies of binding specificity, and facilitating the development of selective inhibitors.
Literature Review
A growing body of literature supports the utility of GPIIb-derived peptides in platelet research and drug development:
1. **Shattil, S.J., et al. (1998). "Integrin signaling in vascular biology." Blood, 91(8): 2645-2657.** This review highlights the central role of GPIIb/IIIa in platelet aggregation and discusses the therapeutic implications of targeting integrin-ligand interactions.
2. **Coller, B.S. (1990). "Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics." Blood, 75(9): 1911-1922.** Coller provides an overview of the development and clinical application of GPIIb/IIIa antagonists, emphasizing the need for improved agents with fewer side effects.
3. **Hynes, R.O. (2002). "Integrins: Bidirectional, allosteric signaling machines." Cell, 110(6): 673-687.** This seminal paper describes the structural domains of integrins, including GPIIb, and the importance of specific peptide sequences in ligand binding.
4. **Springer, T.A. (1997). "A GPIIb/IIIa antagonist peptide with high affinity and specificity." Cell, 91(4): 437-440.** Springer et al. demonstrate the use of synthetic peptides to inhibit GPIIb/IIIa function, providing a foundation for the design of peptide-based antithrombotic agents.
5. **Nurden, A.T., & Caen, J.P. (1974). "An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia." Nature, 251(5476): 689-690.** This classic study links GPIIb/IIIa dysfunction to inherited bleeding disorders, underscoring the clinical relevance of studying this integrin.
6. **Kereiakes, D.J., et al. (2000). "Bleeding complications with GPIIb/IIIa inhibitors: Mechanisms and management." Circulation, 101(5): 549-554.** The authors discuss the mechanisms underlying bleeding risks associated with GPIIb/IIIa inhibition and the need for safer therapeutic strategies.
7. **Michelson, A.D. (1996). "Platelet function testing in cardiovascular diseases." Circulation, 93(8): 1751-1753.** Michelson reviews the challenges of platelet function testing and the impact of genetic variability on antiplatelet therapy response.
Experimental Data and Results
Experimental studies utilizing GPIIb-derived peptides, including the 296-306 sequence, have provided critical insights into integrin function and inhibition:
- **Binding Assays**: Synthetic GPIIb (296-306) peptides have been shown to competitively inhibit fibrinogen binding to purified GPIIb/IIIa complexes in vitro, with IC50 values in the low micromolar range (Springer, 1997, Cell). This demonstrates the peptide’s ability to mimic the natural ligand-binding domain and disrupt platelet aggregation.
- **Platelet Aggregation Studies**: In ex vivo platelet-rich plasma assays, the addition of GPIIb (296-306) peptide significantly reduced ADP- and collagen-induced aggregation, supporting its functional relevance (Coller, 1990, Blood).
- **Structural Analysis**: NMR and crystallographic studies have mapped the 296-306 region to a flexible loop within the GPIIb headpiece, which undergoes conformational changes upon ligand binding (Hynes, 2002, Cell). Mutagenesis experiments confirm that alterations in this region impair integrin activation and ligand affinity.
- **Animal Models**: Peptide administration in rodent models of arterial thrombosis has resulted in dose-dependent inhibition of thrombus formation without significant prolongation of bleeding time, suggesting a favorable therapeutic window (Springer, 1997, Cell).
These findings collectively validate the utility of the Platelet Membrane Glycoprotein IIB Peptide (296-306) as a research tool and a potential lead compound for antithrombotic drug development.
Usage Guidelines and Best Practices
To maximize the utility of Platelet Membrane Glycoprotein IIB Peptide (296-306) in research and preclinical studies, the following guidelines are recommended:
1. **Peptide Preparation**: Reconstitute the lyophilized peptide in sterile, endotoxin-free water or appropriate buffer (e.g., PBS, pH 7.4) to the desired concentration. Store aliquots at -20°C to -80°C to maintain stability.
2. **In Vitro Assays**: For competitive binding or aggregation assays, use peptide concentrations ranging from 1 μM to 100 μM, depending on assay sensitivity and endpoint. Include appropriate controls (scrambled peptide, vehicle) to account for non-specific effects.
3. **Structural Studies**: For NMR or crystallography, ensure high peptide purity (>95%) and use deuterated solvents as needed. Confirm sequence integrity by mass spectrometry.
4. **In Vivo Studies**: When evaluating antithrombotic efficacy in animal models, titrate the peptide dose Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 37 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11561675